| __timestamp | Viatris Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 581800000 | 293000 |
| Thursday, January 1, 2015 | 671900000 | 1002000 |
| Friday, January 1, 2016 | 876700000 | 888000 |
| Sunday, January 1, 2017 | 857900000 | 19623000 |
| Monday, January 1, 2018 | 822200000 | 30421000 |
| Tuesday, January 1, 2019 | 778200000 | 34794000 |
| Wednesday, January 1, 2020 | 512600000 | 28304000 |
| Friday, January 1, 2021 | 681000000 | 56886000 |
| Saturday, January 1, 2022 | 662200000 | 100894000 |
| Sunday, January 1, 2023 | 910700000 | 159765000 |
Data in motion
In the ever-evolving pharmaceutical landscape, innovation is the key to staying ahead. Viatris Inc. and Viridian Therapeutics, Inc. are two companies that have taken distinct paths in their investment strategies. Over the past decade, Viatris has consistently outpaced Viridian in research and development (R&D) spending. In 2023, Viatris invested nearly 21 times more in R&D than Viridian, highlighting its commitment to innovation.
From 2014 to 2023, Viatris's R&D expenses grew by approximately 56%, peaking at $910 million in 2023. In contrast, Viridian's R&D spending, while increasing significantly, started from a modest base, reaching $160 million in 2023. This disparity underscores Viatris's robust financial commitment to innovation, while Viridian's growth trajectory suggests a strategic pivot towards increased R&D investment. As the pharmaceutical industry continues to evolve, these investment patterns will shape the future of both companies.
Research and Development Expenses Breakdown: Eli Lilly and Company vs Viatris Inc.
Bristol-Myers Squibb Company vs Viatris Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Incyte Corporation and Viridian Therapeutics, Inc.
Research and Development Investment: Viatris Inc. vs Exelixis, Inc.
Comparing Innovation Spending: Viatris Inc. and Opthea Limited
Research and Development: Comparing Key Metrics for Viatris Inc. and Alpine Immune Sciences, Inc.
Comparing Innovation Spending: Viatris Inc. and CRISPR Therapeutics AG
Viatris Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Pharming Group N.V. or Viridian Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Iovance Biotherapeutics, Inc. and Viridian Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd. or Viridian Therapeutics, Inc.: Who Invests More in Innovation?